CIK: 0001637359 · Show all filings
Period: Q3 2024 (← Previous) (Next →)
Filing Date: Nov 14, 2024
Total Value ($000): $160,009 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | 2,204,650 | $56,152 | 35.1% | $25.50 | 0.0% | Common Stock | 055477103 |
| NUVB | Nuvation Bio | 13,072,340 | $29,936 | 18.7% | $11.18 | -72.7% | Common Stock Class A | 67080N101 |
| REPL | Replimune Group | 2,461,319 | $26,976 | 16.9% | $17.40 | -41.6% | Common Stock | 76029N106 |
| LXEO | Lexeo Therapeutics | 2,355,904 | $21,297 | 13.3% | $12.69 | -6.0% | Common Stock | 52886X107 |
| ENGN | enGene Holdings Inc. | 1,076,357 | $7,104 | 4.4% | $10.40 | -28.5% | Common Stock | 29286M105 |
| ALMS | Alumis Inc | 653,223 | $6,976 | 4.4% | $13.30 | -8.8% | Common Stock | 022307102 |
| — | Ikena Oncology | 2,249,123 | $3,891 | 2.4% | $28.25 | — | Common Stock | 45175G108 |
| SANA | Sana Biotechnology, Inc. | 843,750 | $3,510 | 2.2% | $32.56 | -83.9% | Common Stock | 799566104 |
| IMUX | Immunic Inc | 1,788,160 | $2,950 | 1.8% | $13.89 | -89.8% | Common Stock | 4525EP101 |
| ENGNW | enGene Holdings Inc. | 321,502 | $675 | 0.4% | $0.85 | — | Warrant | 29286M113 |
| SYRS | Syros Pharmaceuticals | 251,270 | $540 | 0.3% | $8.12 | -55.8% | Common Stock | 87184Q206 |